Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Sunday. The brokerage issued a hold rating on the stock.

Several other research firms have also recently commented on EKSO. Lake Street Capital started coverage on shares of Ekso Bionics in a research report on Monday, June 24th. They set a buy rating and a $2.50 target price on the stock. HC Wainwright reiterated a buy rating and issued a $10.00 price objective on shares of Ekso Bionics in a research note on Tuesday, July 30th.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $1.19 on Friday. Ekso Bionics has a fifty-two week low of $0.62 and a fifty-two week high of $3.13. The stock has a market cap of $21.94 million, a price-to-earnings ratio of -1.23 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. The firm’s 50-day simple moving average is $1.11 and its 200 day simple moving average is $1.25.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The business had revenue of $4.95 million during the quarter, compared to the consensus estimate of $5.34 million. During the same period in the previous year, the business posted ($0.31) EPS. As a group, research analysts anticipate that Ekso Bionics will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.